Generalized Myasthenia Gravis Market Expected to Experience Major Growth by 2034, According to DelveInsight | Viela Bio, UCB Pharma, Ra Pharma, Argenx, Alexion Pharma, Takeda, Argenx-Halozyme Therapeu

The Key Generalized Myasthenia Gravis Companies in the market include - Viela Bio, UCB Pharma, Ra Pharmaceuticals, Argenx, Alexion Pharmaceuticals, Takeda, Argenx-Halozyme Therapeutics, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, DAS Therapeutics, Inc., and others.
DelveInsight's "Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Generalized Myasthenia Gravis, historical and forecasted epidemiology as well as the Generalized Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Generalized Myasthenia Gravis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Generalized Myasthenia Gravis Market Forecast [https://www.delveinsight.com/sample-request/generalized-myasthenia-gravis-gmg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Generalized Myasthenia Gravis Market Report:

*
The Generalized Myasthenia Gravis market size was valued approximately ~USD 2,700 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In April 2025, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotech company advancing cell therapies for autoimmune disorders, announced 12-month efficacy and safety results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Participants receiving a single six-week Descartes-08 treatment showed sustained symptom improvement at 12 months. The findings will be discussed by company leadership at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025, and presented by Dr. Tuan Vu, Professor of Neurology at the University of South Florida Morsani College of Medicine, at the 2025 American Academy of Neurology Annual Meeting on April 9, 2025.

*
In April 2025, Remarkable findings from the Phase 3 clinical trial (NCT05737160) assessing the efficacy and safety of Telitacicept (also known as RC18; brand name: Registered ) in patients with generalized myasthenia gravis (gMG) were unveiled during the Late-Breaking Science Session at the American Academy of Neurology (AAN) Annual Meeting.

*
In March 2025, Johnson & Johnson (NYSE: JNJ) announced that 12 abstracts-featuring two oral presentations-will be showcased at the 2025 American Academy of Neurology (AAN) Annual Meeting. These presentations will emphasize the company's advancements in autoantibody disease research and the potential of nipocalimab to offer sustained, long-term disease control in treating generalized myasthenia gravis (gMG).

*
In January 2025, The U.S. Food and Drug Administration (FDA) has granted Priority Review to Johnson & Johnson's Biologics License Application (BLA) for nipocalimab, a treatment for generalized myasthenia gravis (gMG) in patients who are antibody-positive, including those with anti-AChR, anti-MuSK, and anti-LRP4 antibodies.

*
In October 2024, Amgen (NASDAQ:AMGN) has announced the presentation of favorable top-line results from the Phase 3 MINT trial, which assessed the efficacy and safety of UPLIZNA Registered (inebilizumab-cdon) in treating adults with generalized myasthenia gravis (gMG), a rare autoimmune disease.

*
In August 2024, Merck KGaA (Merck) administered the first dose in a Phase III trial of oral Cladribine for treating generalized myasthenia gravis (gMG), a rare neuromuscular condition. Named MyClad, this international, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of Cladribine capsules in comparison to a placebo.

*
In June 2024, Johnson & Johnson (NYSE: JNJ) announced positive findings from the Phase 3 Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia gravis (gMG). Patients receiving nipocalimab in combination with standard of care (SOC) showed superior results compared to those treated with placebo and SOC, as indicated by the primary endpoint of improvement in the MG-ADL score from baseline over 24 weeks. These results will be featured in a presentation at the European Academy of Neurology (EAN) 2024 Congress and will be part of submissions to regulatory authorities later this year.

*
In January 2024, RYSTIGGO Registered (rozanolixizumab-noli) is a targeted treatment approved for adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.

*
In February 2024, Johnson & Johnson (J&J) unveiled favorable top-line findings for nipocalimab across two rare disease categories: generalized myasthenia gravis (gMG) and Sjogren's disease. These achievements follow positive outcomes observed in two other autoantibody-related conditions, namely, haemolytic disease of the foetus and newborn (HDFN) and rheumatoid arthritis (RA). The Phase III VIVACITY trial (NCT03772587) of nipocalimab in adult gMG patients achieved its primary objective, demonstrating a statistically significant decrease in daily activity scores (measured by the myasthenia gravis activities of daily living scale - MG-ADL) from baseline over a period of 22 to 24 weeks, relative to placebo.

*
In 2021, the market size for Generalized Myasthenia Gravis (gMG) across the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan was estimated to be around USD 2,700 million.

*
According to Suresh et al. (2021), there are 20 cases of myasthenia gravis for every 100,000 people in the United States. It shows that those under 40 have a higher female predominance, while people over 50 have a higher male predominance

*
The prevalence of MG varies from 1.5 to 17.9, or 2.19 to 36.71 cases/100.000 population, depending on the region. This suggests that there are roughly 60.000 sufferers in the US and 56,000-123,000 in Europe

*
According to a Green et al. (2020) study, 5.6% of the North American sample had non-family myasthenia gravis. While the majority of instances of myasthenia gravis are still not familial, a prevalence of 5.6% is several hundred times higher than the overall prevalence of 1 in 5-10 000 cases of the condition

*
Key Generalized Myasthenia Gravis Companies: Viela Bio, UCB Pharma, Ra Pharmaceuticals, Argenx, Alexion Pharmaceuticals, Takeda, Argenx-Halozyme Therapeutics, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, DAS Therapeutics, Inc., and others

*
Key Generalized Myasthenia Gravis Therapies: Inebilizumab, Rozanolixizumab, Zilucoplan, Efgartigimod, Eculizumab, TAK-079, Subcutaneous Efgartigimod, Uplizna (Inebilizumab), Enspryng (Satralizumab), Nipocalimab, Batoclimab, Tolebrutinib, Descartes-08, Mezagitamab (TAK-079), DAS-001, and others

*
The Generalized Myasthenia Gravis epidemiology based on gender analyzed that prevalence of Generalized Myasthenia Gravis is higher in females than males

*
The Generalized Myasthenia Gravis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Generalized Myasthenia Gravis pipeline products will significantly revolutionize the Generalized Myasthenia Gravis market dynamics.

Generalized Myasthenia Gravis Overview

Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disorder that causes muscle weakness. It occurs when the immune system produces antibodies that disrupt communication between nerves and muscles, targeting proteins like the acetylcholine receptor or related components at the neuromuscular junction.

Symptoms of gMG include weakness in the arms, legs, neck, eyes (causing drooping eyelids or double vision), and difficulties with speaking, swallowing, and breathing. The severity of symptoms can vary and may worsen with activity but improve with rest.

Get a Free sample for the Generalized Myasthenia Gravis Market Report:

https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market [https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Generalized Myasthenia Gravis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Generalized Myasthenia Gravis Epidemiology Segmentation:

The Generalized Myasthenia Gravis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Generalized Myasthenia Gravis

*
Prevalent Cases of Generalized Myasthenia Gravis by severity

*
Gender-specific Prevalence of Generalized Myasthenia Gravis

*
Diagnosed Cases of Episodic and Chronic Generalized Myasthenia Gravis

Download the report to understand which factors are driving Generalized Myasthenia Gravis epidemiology trends @ Generalized Myasthenia Gravis Epidemiology Forecast [https://www.delveinsight.com/sample-request/generalized-myasthenia-gravis-gmg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Generalized Myasthenia Gravis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Myasthenia Gravis market or expected to get launched during the study period. The analysis covers Generalized Myasthenia Gravis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Generalized Myasthenia Gravis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Generalized Myasthenia Gravis Therapies and Key Companies

*
Inebilizumab: Viela Bio

*
Rozanolixizumab: UCB Pharma

*
Zilucoplan: Ra Pharmaceuticals

*
Efgartigimod: Argenx

*
Eculizumab: Alexion Pharmaceuticals

*
TAK-079: Takeda

*
Subcutaneous Efgartigimod: Argenx-Halozyme Therapeutics

*
Uplizna (Inebilizumab): Horizon Therapeutics

*
Enspryng (Satralizumab): Hoffmann-La Roche

*
Nipocalimab: Janssen Research & Development, LLC

*
Batoclimab: Immunovant Sciences GmbH

*
Tolebrutinib: Sanofi

*
Descartes-08: Cartesian Therapeutics

*
Mezagitamab (TAK-079): Takeda

*
DAS-001: DAS Therapeutics, Inc.

Discover more about therapies set to grab major Generalized Myasthenia Gravis market share @ Generalized Myasthenia Gravis Treatment Market [https://www.delveinsight.com/sample-request/generalized-myasthenia-gravis-gmg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Generalized Myasthenia Gravis Market Strengths

*
Growing research and development is increasing the demand for better diagnosis and treatment options for MG.

*
Approval of targeted therapies such as Soliris, Vygart, and Ultomiris will fuel the market growth.

Generalized Myasthenia Gravis Market Opportunities

*
Approval of new therapies will provide better treatment options

*
Various big Pharma key players are currently active in the development of a novel drug for the treatment of MG.

Scope of the Generalized Myasthenia Gravis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Generalized Myasthenia Gravis Companies: Viela Bio, UCB Pharma, Ra Pharmaceuticals, Argenx, Alexion Pharmaceuticals, Takeda, Argenx-Halozyme Therapeutics, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, DAS Therapeutics, Inc., and others

*
Key Generalized Myasthenia Gravis Therapies: Inebilizumab, Rozanolixizumab, Zilucoplan, Efgartigimod, Eculizumab, TAK-079, Subcutaneous Efgartigimod, Uplizna (Inebilizumab), Enspryng (Satralizumab), Nipocalimab, Batoclimab, Tolebrutinib, Descartes-08, Mezagitamab (TAK-079), DAS-001, and others

*
Generalized Myasthenia Gravis Therapeutic Assessment: Generalized Myasthenia Gravis current marketed and Generalized Myasthenia Gravis emerging therapies

*
Generalized Myasthenia Gravis Market Dynamics: Generalized Myasthenia Gravis market drivers and Generalized Myasthenia Gravis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Generalized Myasthenia Gravis Unmet Needs, KOL's views, Analyst's views, Generalized Myasthenia Gravis Market Access and Reimbursement

To know more about Generalized Myasthenia Gravis companies working in the treatment market, visit @ Generalized Myasthenia Gravis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/generalized-myasthenia-gravis-gmg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Generalized Myasthenia Gravis Market Report Introduction

2. Executive Summary for Generalized Myasthenia Gravis

3. SWOT analysis of Generalized Myasthenia Gravis

4. Generalized Myasthenia Gravis Patient Share (%) Overview at a Glance

5. Generalized Myasthenia Gravis Market Overview at a Glance

6. Generalized Myasthenia Gravis Disease Background and Overview

7. Generalized Myasthenia Gravis Epidemiology and Patient Population

8. Country-Specific Patient Population of Generalized Myasthenia Gravis

9. Generalized Myasthenia Gravis Current Treatment and Medical Practices

10. Generalized Myasthenia Gravis Unmet Needs

11. Generalized Myasthenia Gravis Emerging Therapies

12. Generalized Myasthenia Gravis Market Outlook

13. Country-Wise Generalized Myasthenia Gravis Market Analysis (2020-2034)

14. Generalized Myasthenia Gravis Market Access and Reimbursement of Therapies

15. Generalized Myasthenia Gravis Market Drivers

16. Generalized Myasthenia Gravis Market Barriers

17. Generalized Myasthenia Gravis Appendix

18. Generalized Myasthenia Gravis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=generalized-myasthenia-gravis-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-viela-bio-ucb-pharma-ra-pharma-argenx-alexion-pharma-takeda-argenxhalozyme-therapeu]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.